CohBar Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Welcome to the H.C. Wainwright 5th Annual NASH Conference. For our next presentation, we have Dr. Joseph Sarret, CEO of CohBar, a clinical stage company developing mitochondria-based therapeutics for chronic diseases. Dr. Sarret, very good to have you with us. Please go ahead with your presentation.
Thanks, Thomas. Appreciate the opportunity here to speak with you today and tell you more about CohBar and the exciting work we are doing in the area of NASH. Just as a reminder, CohBar is a public company so typical forward-looking statement warnings apply to my remarks today.
So CohBar, in terms of our overall approach, what we are doing is we are leveraging the power of mitochondrial genome to develop novel peptide therapeutics. As you may be aware, people have been looking at the nuclear genome for quite some time, but mitochondrial has been largely overlooked. I think for a couple of reasons. One is people tend to think of mitochondria in terms of ATP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
